{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:10:30Z","timestamp":1777011030138,"version":"3.51.4"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"HHS | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002553 #A03-0077"],"award-info":[{"award-number":["UL1TR002553 #A03-0077"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"HHS | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS085049"],"award-info":[{"award-number":["K23NS085049"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:p>Botulism is a rare, life-threatening paralytic disease caused by botulinum neurotoxin (BoNT). Available treatments including an equine antitoxin and human immune globulin are given postexposure and challenging to produce and administer.<\/jats:p>","DOI":"10.1128\/aac.01732-21","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T13:31:11Z","timestamp":1647869471000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-1564","authenticated-orcid":true,"given":"S. M.","family":"Raja","sequence":"first","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. T.","family":"Guptill","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"},{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"Juel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"},{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hill","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sendra","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tomic","sequence":"additional","affiliation":[{"name":"Ology Bioservices Incorporated, Alameda, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Ology Bioservices Incorporated, Alameda, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-6993","authenticated-orcid":true,"given":"G. K.","family":"Swamy","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.130.3378.763"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11120686"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12010009"},{"key":"e_1_3_2_5_2","volume-title":"Botulism annual summary, 2017.","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. 2019. Botulism annual summary, 2017. Department of Health and Human Services, CDC, Atlanta, Georgia."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152a3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000370245"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1504248"},{"key":"e_1_3_2_10_2","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051926"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152607780090667"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666141022093350"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00261"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2018.01.012"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02830-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01270-19"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02329-20"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172229899"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.1.570-574.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11060345"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11040208"},{"key":"e_1_3_2_23_2","unstructured":"Anonymous. 2017. BAT(R) [botulism antitoxin heptavalent (A B C D E F G) - (equine)] sterile solution for injection [package insert]. Cangene Corportation Winnipeg Manitoba (Canada)."},{"key":"e_1_3_2_24_2","volume-title":"Investigational brochure: anti-BoNT E antibody (NTM-1633) treatment and prevention of type E botulism poisoning, version 1.0.","author":"Ology Bioservices Incorporated","year":"2018","unstructured":"Ology Bioservices Incorporated. 2018. Investigational brochure: anti-BoNT E antibody (NTM-1633) treatment and prevention of type E botulism poisoning, version 1.0. Ology Bioservices, Alameda, CA."},{"key":"e_1_3_2_25_2","unstructured":"NIAID. 2002. NIAID biodefense research agenda for CDC category A agents. U.S. Department of Health and Human Services Washington DC. http:\/\/sp.xoma.com\/sites\/RefLib\/Library\/niaid-2002.pdf."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12706"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.09.030"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01732-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01732-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:18:26Z","timestamp":1650374306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01732-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,19]]}},"alternative-id":["10.1128\/aac.01732-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01732-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"2021-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01732-21"}}